Conner CS - Search Results

1

The changing landscape of type 2 diabetes: the role of incretin-based therapies in managed care outcomes.

Triplitt C, McGill JB, Porte D Jr, Conner CS. Triplitt C, et al. Among authors: conner cs. J Manag Care Pharm. 2007 Dec;13(9 Suppl C):S2-16; quiz S17. doi: 10.18553/jmcp.2007.13.9-c.1. J Manag Care Pharm. 2007. PMID: 18062735 Free PMC article. Review.

2

The intersection of safety and adherence: new incretin-based therapies in patients with type 2 diabetes mellitus.

Zarowitz BJ, Conner C. Zarowitz BJ, et al. Pharmacotherapy. 2009 Dec;29(12 Pt 2):55S-67S. doi: 10.1592/phco.29.pt2.55S. Pharmacotherapy. 2009. PMID: 19947817 Review.

3

A review of diabetes treatment adherence and the association with clinical and economic outcomes.

Asche C, LaFleur J, Conner C. Asche C, et al. Clin Ther. 2011 Jan;33(1):74-109. doi: 10.1016/j.clinthera.2011.01.019. Clin Ther. 2011. PMID: 21397776 Review.

4

A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus.

Sullivan SD, Alfonso-Cristancho R, Conner C, Hammer M, Blonde L. Sullivan SD, et al. Pharmacotherapy. 2009 Nov;29(11):1280-8. doi: 10.1592/phco.29.11.1280. Pharmacotherapy. 2009. PMID: 19873688 Clinical Trial.

5

A comparison of preferences for two GLP-1 products--liraglutide and exenatide--for the treatment of type 2 diabetes.

Polster M, Zanutto E, McDonald S, Conner C, Hammer M. Polster M, et al. J Med Econ. 2010;13(4):655-61. doi: 10.3111/13696998.2010.529377. Epub 2010 Nov 1. J Med Econ. 2010. PMID: 21034377 Free article.

6

Association between hypoglycaemic events and fall-related fractures in Medicare-covered patients with type 2 diabetes.

Johnston SS, Conner C, Aagren M, Ruiz K, Bouchard J. Johnston SS, et al. Diabetes Obes Metab. 2012 Jul;14(7):634-43. doi: 10.1111/j.1463-1326.2012.01583.x. Epub 2012 Mar 14. Diabetes Obes Metab. 2012. PMID: 22335246

7

Concurrent control of blood glucose, body mass, and blood pressure in patients with type 2 diabetes: an analysis of data from electronic medical records.

McAdam-Marx C, Bouchard J, Aagren M, Conner C, Brixner DI. McAdam-Marx C, et al. Clin Ther. 2011 Jan;33(1):110-20. doi: 10.1016/j.clinthera.2011.01.018. Clin Ther. 2011. PMID: 21397777

8

Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.

Lee WC, Conner C, Hammer M. Lee WC, et al. Clin Ther. 2010 Sep;32(10):1756-67. doi: 10.1016/j.clinthera.2010.08.010. Clin Ther. 2010. PMID: 21194600

9

Adherence and persistence to a regimen of basal insulin in a pre-filled pen compared to vial/syringe in insulin-naïve patients with type 2 diabetes.

Buysman E, Conner C, Aagren M, Bouchard J, Liu F. Buysman E, et al. Curr Med Res Opin. 2011 Sep;27(9):1709-17. doi: 10.1185/03007995.2011.598500. Epub 2011 Jul 11. Curr Med Res Opin. 2011. PMID: 21740289

10

Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US.

Lee WC, Conner C, Hammer M. Lee WC, et al. Curr Med Res Opin. 2011 May;27(5):897-906. doi: 10.1185/03007995.2011.559444. Epub 2011 Feb 25. Curr Med Res Opin. 2011. PMID: 21348806 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

54 results

Search Page

Filters